Exhibition Menu +
Sections +

Avian Flu: Risks, Treatment and the HIV/AIDS Link

A worker disinfects ducks at a poultry farm in Shanghai's Nanhui District. (quiplash/flickr)
by Stephanie Valera
8 November 2005

Asia Society held a video conference on November 1, 2005 of a
discussion on Avian Flu with the Honorable Michael Leavitt, Secretary,
United States Department of Health and Human Services. Dr. Ian Lipkin
of the Mailman School of Public Health at Columbia Univeristy presided.

Information on Avian Influenza: H5N1

A Brief Overview of the Current Situation

The H5N1 avian influenza strain, which has killed millions of
domestic birds and 53 known humans in the last few years, is on the
tipping point of infecting millions world-wide, capable of unleashing a
pandemic that could equal or greatly surpass the Spanish Flu of 1918. 
Of the 20-100 million people worldwide that died in 1918, the most
victimized demographic was 10-35 year olds.  Unlike the seasonal
influenza strains that inflect millions every year and present a
serious threat only to children and the elderly, a severe strain of
influenza like H5N1 would not simply attack the weak.  No human has
immunity built up against H5N1; if it undergoes antigenic shift with a
human influenza virus, the disease that has a 100% death rate in
chickens would (even in a mild pandemic situation) wreak havoc on
global health, the global economy, and global security.

All signs point to an H5N1 pandemic, including an increased
virulence of the strain in recent samples and the infection and deaths
of migratory birds that traditionally carry the virus but show no
symptoms.  The primary question that remains is not if the pandemic will occur, but when.

The Additional Risks for China and the Asia-Pacific Region

Outbreak is an especially high risk in China; as the Chinese GDP
has grown, more people can now afford to eat chicken.  This has caused
chicken farming to become an enormous industry in China, an industry
upon which over a billion people rely for food. Asian consumer
practices also do not bode well for an avian-spread disease,
specifically the preference to buy live chickens at large outdoor (and
often unsanitary) markets for slaughter at home.

Treatment: Vaccine Production

The optimal treatment for H5N1 is unknown; the WHO has
recommended that countries stockpile Oseltamivir (produced by the Roche
pharmaceutical company under the name Tamiflu).  While Tamiflu was
shown to be helpful in combating the virus in certain cases, its
success has by no means been universal.  There are very few
pharmaceutical companies interested in producing vaccines –
financially, vaccines are a risky investment for a variety of reasons. 
Flu vaccines currently comprise 2% of the global pharmaceutical
market.  Because of the seasonal nature of the virus, flu vaccines must
be made rapidly (which subsequently increases the risk of both
contamination and error).  Each year the WHO participates in vaccine
development by deciding every February which particular strains will be
most prominent in the upcoming season.  Given the time it takes to
produce vaccines (and the fact that only nine countries have the
capabilities, with only a handful of willing pharmaceutical companies
interested), it is not until September or October that the vaccines are
available, usually just in time for the start of the North American flu
season.  Because the Asian flu season typically begins in the early
summer, there is no way to get vaccines to Asia in time.  And even if
there were a way, there is still the issue of quantity.

annual production of influenza vaccine is limited to about 300 million
trivalent doses.  To counter a new strain of pandemic influenza that
has never circulated throughout the population, each person would most
likely need two doses for adequate protection.  In a best-case
scenario, less than 500 million people (14% of the world’s population)
would be vaccinated within one year of the pandemic’s outbreak.  That
timetable does not factor in the six additional months that are
required to develop the vaccine before mass production can commence.


should be noted that H5N1 would initially strike a similar population
to one currently victimized by HIV/AIDS, namely Asia.  Given the
weakened state of their immune system, HIV+ individuals would almost
certainly die from exposure to H5N1.  Organizations concerned with
fighting AIDS must therefore also devote a significant amount of
attention to the H5N1 threat.

Any discussion of how H5N1
pertains to national security must apply the lessons of the relatively
slow threat of HIV/AIDS to a much faster H5N1 capable of human-to-human
transfer.  See Laurie Garrett’s article “The Lessons of HIV/AIDS” in
the July/August 2005 issue of Foreign Affairs for more on this topic.

Also related: The 2005 Review of UN Resolution 1308 on the HIV/AIDS threat to global stability and security.

The Lessons of SARS

In the case of the SARS epidemic, the impacts of the actual
public health threat and the subsequent $40 billion of economic losses
in the Asia-Pacific region over six months were insignificant compared
to the political implications of the PRC’s failure to allay panic
through the withholding of information from its people. 

Secondary Threats

immediate public health threat, namely the possible millions of deaths
worldwide, should not be the only concern.  Even a moderate pandemic
would result in economic losses too vast to imagine.  Entire industries
would be destroyed (not simply farming), international borders would
close, medical costs would skyrocket, and most importantly, the largest
productivity drop in modern history would occur.

These factors
would inevitably cause worldwide panic.  Panic from the public halfway
around the world that watches cable news, panic from big business, and
panic from governments.  The security concerns involved are too
far-reaching to estimate.